{"organizations": [], "uuid": "6b2b59d9d02992ce9674df418365dd4c5ce38e37", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/03/globe-newswire-rewalk-robotics-appoints-yohanan-engelhardt-to-its-board-of-directors-and-as-chairman-of-the-audit-committee.html", "country": "US", "domain_rank": 767, "title": "ReWalk Robotics Appoints Yohanan Engelhardt to its Board of Directors and as Chairman of the Audit Committee", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-04T00:30:00.000+03:00", "replies_count": 0, "uuid": "6b2b59d9d02992ce9674df418365dd4c5ce38e37"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/03/globe-newswire-rewalk-robotics-appoints-yohanan-engelhardt-to-its-board-of-directors-and-as-chairman-of-the-audit-committee.html", "ord_in_thread": 0, "title": "ReWalk Robotics Appoints Yohanan Engelhardt to its Board of Directors and as Chairman of the Audit Committee", "locations": [], "entities": {"persons": [{"name": "yohanan engelhardt", "sentiment": "negative"}, {"name": "engelhardt", "sentiment": "none"}, {"name": "yohanan", "sentiment": "none"}], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "yokneam", "sentiment": "none"}, {"name": "marlborough", "sentiment": "none"}, {"name": "israel", "sentiment": "none"}, {"name": "viryanet", "sentiment": "none"}], "organizations": [{"name": "audit committee", "sentiment": "negative"}, {"name": "rewalk robotics", "sentiment": "negative"}, {"name": "rewalk robotics, ltd", "sentiment": "neutral"}, {"name": "sec", "sentiment": "none"}, {"name": "sox", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, May 03, 2018 (GLOBE NEWSWIRE) -- ReWalk Robotics, Ltd. (Nasdaq:RWLK) (“ReWalk” or “the Company”) announced today that the Company has appointed Yohanan Engelhardt to the Board of Directors and as Chairman of its Audit Committee.\nMr. Engelhardt is a seasoned financial executive who has spent the last 25 years helping companies realize enterprise-wide improvements in financial reporting, financial and operational controls and expenses, capital funding, and taxation.\nMr. Engelhardt provides CFO-consulting accounting services to early-stage technology and medical device companies. From 1996-2014 Mr. Engelhardt served as the Chief Financial Officer and VP of Finance at ViryaNet, a publicly-traded company, in which he oversaw all financial operations including SEC reporting, planning and forecasting, audits, business analysis, accounting, tax, treasury, strategic planning and SOX compliance, and managed all financial and capital structure functions.\n“We are pleased to welcome Yohanan to our Board of Directors. His financial acumen and expertise will be invaluable as we continue to build ReWalk and expand our product portfolio. We look forward to his leadership and guidance,” said ReWalk CEO Larry Jasinski.\nAbout ReWalk Robotics Ltd.\nReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. The company’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit www.rewalk.com .\nReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel.\nForward-Looking Statements\nIn addition to historical information, this press release contains within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such may include projections regarding ReWalk’s future performance and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek” and similar terms or phrases. The contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk’s control. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the include, among others: ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets, and to expand to new markets and achieve its planned expense reductions; the conclusion of ReWalk’s management and the opinion of ReWalk’s auditors for the Company’s financial statements for the fiscal year ended December 31, 2017, that there are substantial doubts as to ReWalk’s ability to continue as a going concern; ReWalk’s ability to maintain and grow its reputation and the market acceptance of its products; ReWalk’s ability to achieve reimbursement from third-party payors for its products; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s expectations as to the results of, and the Food and Drug Administration’s potential regulatory developments with respect to, ReWalk’s mandatory post-market 522 surveillance study; the outcome of ongoing shareholder class action litigation relating to ReWalk’s initial public offering; ReWalk’s ability to repay its secured indebtedness; ReWalk’s ability to improve its products and develop new products; ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s ability to secure capital from its equity and debt financings in light of limitations under its Form S-3, the price range of its ordinary shares and conditions in the financial markets, and the risk that such financings may dilute ReWalk’s shareholders or restrict its business; ReWalk’s ability to use effectively the proceeds of offerings of securities; ReWalk’s ability to maintain relationships with existing customers and develop relationships with new customers; the impact of the market price of ReWalk’s ordinary shares on the determination of whether ReWalk is a passive foreign investment company; ReWalk’s ability to regain compliance with the continued listing requirements of the NASDAQ Capital Market and the risk that its ordinary shares will be delisted if it cannot do so; ReWalk’s compliance with medical device reporting regulations to report adverse events involving its products and the potential impact of such adverse events on ReWalk’s ability to market and sell its products; the risk of substantial dilution resulting from the issuance to Timwell; the significant voting power and de facto voting control Timwell will acquire; the risk that the Timwell issuances will fail to close and the China joint venture will not form; and other factors discussed under the heading “Risk Factors” in ReWalk’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission (the “SEC”) and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any , whether as a result of new information, future developments or otherwise.\nInvestor Contact:\nLisa M. Wilson\nPresident\nIn-Site Communications, Inc.\nT: 212-452-2793\nE: lwilson@insitecony.com\nMedia Contact :\nJennifer Wlach\nT: 202-261-4000\nE: media@rewalk.com\nSource:ReWalk Robotics Ltd.", "external_links": ["https://www.globenewswire.com/Tracker?data=qGlGw-I_2kBBgD3xeeIx7F90Ln5e8fUh0qyXhOGea8TKpgNM5lKHMLkqRo9ZQVRzQ2sJZMvTFRvShxs9fZ7VJA==", "https://www.globenewswire.com/Tracker?data=M5-HxqWw6hszONMvJF0KYbCj1g7Q0blz5GNOKGtJ0TvO17KiOpuoviJro7QZmzaQ7RECll-DmIPl9NGN9IqP9g==", "https://www.globenewswire.com/Tracker?data=txQQKfT_lYckHz10NwP3VcNLXsAhnrFOJFDL-2mlc4nApQWGxjUPwOQRrucoTghsAfql1BIACLiajIu_YjwvhySP7HTrFq268iJFwrq1KHM=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/d6d4a2e4-7dde-4214-b5e2-ed404a3d2217"], "published": "2018-05-04T00:30:00.000+03:00", "crawled": "2018-05-04T03:26:53.001+03:00", "highlightTitle": ""}